How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/lower-respiratory-tract-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Lower respiratory tract infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lower respiratory tract infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Lower respiratory tract infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Cefradex	cefradine	Bristol-Myers Squibb	cefradine	Matrix metalloproteinase-9	1974-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 9 drugs in Lower respiratory tract infection
GSK · 5 drugs in Lower respiratory tract infection
Bristol-Myers Squibb · 3 drugs in Lower respiratory tract infection
Pai Holdings Pharm · 2 drugs in Lower respiratory tract infection
Baxter · 1 drug in Lower respiratory tract infection
Bayer AG · 1 drug in Lower respiratory tract infection
Centre Hospitalier Universitaire Vaudois · 1 drug in Lower respiratory tract infection
Eli Lilly · 1 drug in Lower respiratory tract infection
Generic (originally Beecham/GSK) · 1 drug in Lower respiratory tract infection
Generic (originally Roche) · 1 drug in Lower respiratory tract infection
HaEmek Medical Center, Israel · 1 drug in Lower respiratory tract infection
King George's Medical University · 1 drug in Lower respiratory tract infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Lower respiratory tract infection:

Cite this brief

Drug Landscape (2026). Lower respiratory tract infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/lower-respiratory-tract-infection. Accessed 2026-06-11.

Lower respiratory tract infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing